Stockscreener 앱 받기
6.72
5.22%
-0.37
시간 외 거래:
6.85
0.13
+1.93%
전일 마감가:
$7.09
열려 있는:
$7.13
하루 거래량:
1.31M
Relative Volume:
0.72
시가총액:
$307.22M
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-8.0964
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-13.96%
1개월 성능:
+5.66%
6개월 성능:
-27.66%
1년 성능:
-62.18%
1일 변동 폭
$6.695
$7.1577
1주일 범위
$6.695
$7.8199
52주 변동 폭
$5.68
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.72 | 324.13M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
How analysts rate Capricor Therapeutics Inc. stock todayJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
Historical volatility pattern of Capricor Therapeutics Inc. visualizedGDP Growth & Stepwise Trade Execution Plans - newser.com
Heatmap analysis for Capricor Therapeutics Inc. and competitors2025 Price Momentum & Community Verified Trade Alerts - newser.com
How Capricor Therapeutics Inc. stock reacts to job market dataQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - newser.com
Capricor Therapeutics : Investor PresentationOctober 2025 - MarketScreener
What institutional flow reveals about Capricor Therapeutics Inc.2025 Price Targets & Community Consensus Picks - newser.com
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Can trapped investors hope for a rebound in Capricor Therapeutics Inc.New Guidance & Long-Term Safe Investment Plans - newser.com
Is a relief rally coming for Capricor Therapeutics Inc. holdersWeekly Risk Summary & Daily Profit Focused Screening - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Will Capricor Therapeutics Inc. (4LN2) stock outperform energy sector in 2025Weekly Loss Report & Community Driven Trade Alerts - newser.com
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Capricor Therapeutics Inc Stock Analysis and ForecastMomentum Stock Picks & Minimal Investment Capital Gains - earlytimes.in
What drives Capricor Therapeutics Inc 4LN2 stock priceMarket Correction Analysis & Affordable Market Insights - earlytimes.in
Will Capricor Therapeutics Inc. stock see PE expansionInsider Buying & Free Verified High Yield Trade Plans - newser.com
Volume spikes in Capricor Therapeutics Inc. stock – what they meanWeekly Market Report & Daily Technical Forecast Reports - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock profit from AI boom2025 Market Overview & Growth Focused Investment Plans - newser.com
Is Capricor Therapeutics Inc. stock resilient to inflationJuly 2025 Technicals & Community Supported Trade Ideas - newser.com
New Drug for Duchenne Muscular Dystrophy Nears Potential Approval - streetwisereports.com
Capricor Therapeutics Inc. recovery potential after sell off2025 Sector Review & Safe Entry Zone Tips - newser.com
Published on: 2025-10-05 04:39:29 - newser.com
Is Capricor Therapeutics Inc. (4LN2) stock a good hedge against inflation2025 Top Gainers & Community Verified Swing Trade Signals - newser.com
User - FinancialContent
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation - GlobeNewswire
There's Reason For Concern Over Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Massive 26% Price Jump - 富途牛牛
Head to Head Review: Baxter International (NYSE:BAX) and Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Largest borrow rate increases among liquid names - TipRanks
Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy - streetwisereports.com
Biotech Battles FDA, Target Price Shows Potential 90% Gains - streetwisereports.com
Hope On The Horizon As Capricor's HOPE-3 Trial For Duchenne Muscular Dystrophy Nears Data Readout - RTTNews
Is ICICI Prudential Asset Management Co Ltd Stock a Strong Buy According to Wall StreetGlobal Trade Effects & Free Stock Trading Workshops - earlytimes.in
What analysts say about Capricor Therapeutics Inc stockRetail Trading Trends & Low Cost Stock Picks - earlytimes.in
Can Sagardeep Alloys Limited Deliver DoubleDigit Returns in the Next YearStock Liquidity Analysis & Free Stop-Loss Planning for Your Portfolio - earlytimes.in
Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026 (NASDAQ:CAPR) - Seeking Alpha
Why analysts maintain buy rating on Capricor Therapeutics Inc. (4LN2) stock2025 Top Gainers & Trade Opportunity Analysis - newser.com
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
자본화:
|
볼륨(24시간):